#hereditaryangioedema #Otsuka #Ionis #Dawnzera #regulatoryapproval #Rarediseases #pharmanews #HAEdrug #Dawnzera #antisenseoligonucleotidebasedplasmaprekallikreininhibitor #PKKinhibitor #plasmaprekallikreininhibitor #PKK #EMA #HAEpatients #clinicaltrials #RNAtargetedtherapy
zurl.co/Zw7sM
zurl.co/Zw7sM
EU approves Otsuka's long-acting HAE drug Dawnzera
An EMA nod for Otsuka's Dawnzera offers EU patients with HAE a drug that can be self-administered by patients with up to eight weeks between doses.
pharmaphorum.com
January 23, 2026 at 11:17 AM